BioCentury | Dec 21, 2015
Company News

Akebia, Mitsubishi Tanabe Pharma deal

...Philippines, Vietnam, Laos, Cambodia, Thailand, Malaysia, Singapore, Brunei, Myanmar, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Palau...
BioCentury | Sep 28, 2015
Finance

Forbion goes to Spain

...the deal was the second largest venture round raised by a Spanish biotech, behind only Palau Pharma S.A....
BioCentury | Aug 12, 2013
Company News

Palau, Actavis deal

...Actavis acquired worldwide rights to Palau's antifungal agent albaconazole, which is in development to treat vulvo-vaginal...
...broad spectrum oral antifungal has completed a Phase II trial to treat distal subungual onychomycosis. Palau...
...Sage Group advised Palau. Actavis declined to disclose details, and Palau could not be reached. Palau Pharma S.A....
BioCentury | Apr 8, 2013
Emerging Company Profile

Ziarco: Scratching the allergic itch

...atopic dermatitis, which is expected to start in 4Q13, will include specific monitoring for agranulocytosis. Palau Pharma S.A....
...allergic asthma and rhinitis. Yeadon said he did not know how ZPL-3893787 might differ from Palau's...
...Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Palau Pharma S.A....
BioCentury | Jan 3, 2011
Clinical News

UR-63325: Phase IIa started

...to treat allergic rhinitis induced by nasal allergen challenge in 24 otherwise healthy allergic patients. Palau Pharma S.A....
BioCentury | Jun 28, 2010
Clinical News

UR-63325: Phase I data

...volunteers, single-ascending doses of oral UR-63325 were well tolerated with no specific adverse events identified. Palau...
...Data were presented at the European Academy of Allergy and Clinical Immunology meeting in London. Palau Pharma S.A....
BioCentury | Oct 22, 2007
Clinical News

Cimicoxib: Phase II started

...German Phase II trial in 134 patients. The company licensed the compound from Grupo Uriach's Palau...
BioCentury | Oct 15, 2007
Company News

Palau scientific advisory board update

Palau Pharma S.A. , Barcelona, Spain Business: Autoimmune Appointed: Roderick Flower, fellow of the Royal Society and professor at the William Harvey Research Institute's School of Dentistry, as chairman; Josep Grinyo, professor of medicine at the...
BioCentury | Jan 29, 2007
Product Development

COX-2s on the brain

...by academics and internal preclinical research to support its hypotheses. Last week, the company in-licensed Palau...
...good, the company plans to start a Phase IIa trial in 2008. Under the deal, Palau...
BioCentury | Jan 29, 2007
Company News

Affectis, Grupo Uriach deal

...Grupo Uriach's Palau Pharma subsidiary granted Affectis an exclusive worldwide license to cimicoxib to treat all...
...and schizophrenia and expects to start a Phase IIa trial to treat depression this year. Palau...
...undisclosed upfront fee and is eligible for milestones and royalties. Further terms were not disclosed. Palau...
Items per page:
1 - 10 of 11
BioCentury | Dec 21, 2015
Company News

Akebia, Mitsubishi Tanabe Pharma deal

...Philippines, Vietnam, Laos, Cambodia, Thailand, Malaysia, Singapore, Brunei, Myanmar, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Palau...
BioCentury | Sep 28, 2015
Finance

Forbion goes to Spain

...the deal was the second largest venture round raised by a Spanish biotech, behind only Palau Pharma S.A....
BioCentury | Aug 12, 2013
Company News

Palau, Actavis deal

...Actavis acquired worldwide rights to Palau's antifungal agent albaconazole, which is in development to treat vulvo-vaginal...
...broad spectrum oral antifungal has completed a Phase II trial to treat distal subungual onychomycosis. Palau...
...Sage Group advised Palau. Actavis declined to disclose details, and Palau could not be reached. Palau Pharma S.A....
BioCentury | Apr 8, 2013
Emerging Company Profile

Ziarco: Scratching the allergic itch

...atopic dermatitis, which is expected to start in 4Q13, will include specific monitoring for agranulocytosis. Palau Pharma S.A....
...allergic asthma and rhinitis. Yeadon said he did not know how ZPL-3893787 might differ from Palau's...
...Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Palau Pharma S.A....
BioCentury | Jan 3, 2011
Clinical News

UR-63325: Phase IIa started

...to treat allergic rhinitis induced by nasal allergen challenge in 24 otherwise healthy allergic patients. Palau Pharma S.A....
BioCentury | Jun 28, 2010
Clinical News

UR-63325: Phase I data

...volunteers, single-ascending doses of oral UR-63325 were well tolerated with no specific adverse events identified. Palau...
...Data were presented at the European Academy of Allergy and Clinical Immunology meeting in London. Palau Pharma S.A....
BioCentury | Oct 22, 2007
Clinical News

Cimicoxib: Phase II started

...German Phase II trial in 134 patients. The company licensed the compound from Grupo Uriach's Palau...
BioCentury | Oct 15, 2007
Company News

Palau scientific advisory board update

Palau Pharma S.A. , Barcelona, Spain Business: Autoimmune Appointed: Roderick Flower, fellow of the Royal Society and professor at the William Harvey Research Institute's School of Dentistry, as chairman; Josep Grinyo, professor of medicine at the...
BioCentury | Jan 29, 2007
Product Development

COX-2s on the brain

...by academics and internal preclinical research to support its hypotheses. Last week, the company in-licensed Palau...
...good, the company plans to start a Phase IIa trial in 2008. Under the deal, Palau...
BioCentury | Jan 29, 2007
Company News

Affectis, Grupo Uriach deal

...Grupo Uriach's Palau Pharma subsidiary granted Affectis an exclusive worldwide license to cimicoxib to treat all...
...and schizophrenia and expects to start a Phase IIa trial to treat depression this year. Palau...
...undisclosed upfront fee and is eligible for milestones and royalties. Further terms were not disclosed. Palau...
Items per page:
1 - 10 of 11